Advertisement

CD38—Negative Myeloma with Anaplastic Morphology at Presentation: A Case Report

  • Neha Singh
  • Narendra Agrawal
  • Anurag Mehta
  • Ajit Panaych
  • Radhika Sekhri
Letter to the Editor
  • 49 Downloads

Dear Editor,

CD38 is a 46-kDa type II trans-membrane glycoprotein involved in receptor-mediated cell adhesion, signal transduction and intracellular calcium metabolism. Normal plasma cells show higher expression of CD38 than the hematopoietic stem cells, T and B lymphocytes. However, malignant plasma cells over-express CD38 at all stages of maturation. In fact, high and consistent expression of CD38 by myeloma cells together with its significance in cell signaling pathways have suggested the role of CD38 as a potential target for the treatment of multiple myeloma (MM). Daratumumab is a humanized CD38 monoclonal antibody that has emerged as a breakthrough targeted therapy in myeloma patients, used both as a monotherapy and in combination with other agents. Recently published studies have documented loss of CD38 in relapsed or refractory myeloma [1]. Here, we report a case of newly diagnosed MM with CD38 negative plasma cells and anaplastic morphology as evaluated by...

Notes

Compliance with Ethical Standards

Conflict of interest

The authors state that there is no conflict of interest present.

Ethical Approval

This case report does not contain any studies with human participants or animals performed by any of the authors. The identity of the patient is not disclosed here in this case.

Human and Animal Rights

The identity of the patient is not disclosed here in this case.

References

  1. 1.
    Ise M, Matsubayashi K, Tsujimura H, Kumagai K (2016) Loss of CD38 expression in relapsed refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2016.02.037 PubMedGoogle Scholar
  2. 2.
    Sethi Shenon, Miller Ira (2016) Plasma cell myeloma with anaplastic transformation. Blood 128:2106CrossRefPubMedGoogle Scholar
  3. 3.
    Witzig TE, Kimlinger T, Stenson M, Therneau T (1998) Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 31:167–175CrossRefPubMedGoogle Scholar
  4. 4.
    Matsui W, Huff CA, Wang Q et al (2004) Characterization of clono- genic multiple myeloma cells. Blood 103:2332–2336CrossRefPubMedGoogle Scholar
  5. 5.
    Reid S, Yang S, Brown R et al (2010) Characterization and relevance of CD138 negative plasma cells in plasma cell myeloma. Int J Lab Hematol 32:190–196CrossRefGoogle Scholar
  6. 6.
    Kawano Y, Fujiwara S, Wada N et al (2012) Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol 41:876–884CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bataille R, Jego G, Robillard N et al (2006) The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica 91:1234–1240PubMedGoogle Scholar
  8. 8.
    Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125(15):2323–2330CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2017

Authors and Affiliations

  • Neha Singh
    • 1
  • Narendra Agrawal
    • 2
  • Anurag Mehta
    • 1
  • Ajit Panaych
    • 1
  • Radhika Sekhri
    • 1
  1. 1.Department of Pathology and Lab ServicesRajiv Gandhi Cancer Institute and Research CenterRohini, DelhiIndia
  2. 2.Department of Hemato-OncologyRajiv Gandhi Cancer Institute and Research CenterRohini, DelhiIndia

Personalised recommendations